Belimumab therapy within the last 6 months

B-cell-depletion therapy within the last 9 months

heart or kidney insufficiency

known intolerability to Bortezomib

participation in another interventional trial within the last 3 months

liver cirrhosis

preexistent sensory or motor polyneuropathy ≥ degree 2 (NCI CTC AE criteria), within 14 days before screening

hints on clinically apparent herpes zoster reactivation

active systemic infection, or viral infection (CMV, EBV) within last 6 month before screening

serologically active hepatitis B and /or C, known HIV infection

tumor disease currently or within last 5 years

clinically relevant liver, kidney or bone marrow function disorder

pregnancy or lactation

Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)